Accessibility Statement Skip Navigation
  • Back to Global Sites
  • +972-77-2005042
  • Blog
  • Journalists
  • GDPR
  • Send a Release
PR Newswire: news distribution, targeting and monitoring
  • News
  • Products
  • Contact
  • Hamburger menu
  • PR Newswire: news distribution, targeting and monitoring
  • Send a Release
    • Telephone

    • +972-77-2005042 from 8 AM - 11 PM IL

    • Contact
    • Contact

      +972-77-2005042
      from 8 AM - 11 PM IL

  • When typing in this field, a list of search results will appear and be automatically updated as you type.

  • Request More Information
  • Journalists
  • GDPR
  • Request More Information
  • Journalists
  • GDPR
  • Request More Information
  • Journalists
  • GDPR
  • Request More Information
  • Journalists
  • GDPR

Breakthrough in Lupus Treatment: Isotopia Partners with LIVEKIDNEY.BIO
  • USA - Français
  • USA - Deutsch
  • USA - English

Isotopia Logo

News provided by

Isotopia

12 Dec, 2024, 10:00 IST

Share this article

Share toX

Share this article

Share toX

PETACH TIKVA, Israel, Dec. 12, 2024 /PRNewswire/ -- Isotopia is proud to announce a groundbreaking partnership with LIVEKIDNEY.BIO, a clinical-stage biotech innovator, to support the development of a critical component for its revolutionary lupus nephritis therapy. This collaboration offers the potential to improve the lives of lupus patients by providing a more effective treatment solution than what currently exists.

Combining Expertise for a Better Future

This partnership combines LIVEKIDNEY.BIO's pioneering work in lupus treatment with Isotopia's world-class manufacturing capabilities at our state-of-the-art aseptic plant. Our commitment to quality and safety ensures the highest standards in producing a key therapeutic agent for treating lupus.

Understanding Lupus Nephritis

Lupus is a chronic autoimmune disease that afflicts millions of patients worldwide, primarily women aged 15-45. Lupus nephritis can severely affect quality of life and result in kidney failure if not properly managed.

A Significant Step Forward

This collaboration marks a significant milestone in addressing the unmet needs of those afflicted with lupus. By leveraging both companies' strengths, we are propelling advances toward improved care and better outcomes for patients worldwide.

"This collaboration marks a significant step forward in our mission to transform lupus nephritis treatment," said Dr. Alon Yaar, CEO of LIVEKIDNEY.BIO. "By joining forces with Isotopia, we are confident we can provide a much-needed, high-quality solution to improve the lives of millions of lupus patients around the world."

"At Isotopia, we are proud to support innovative solutions that can make a meaningful impact on patient care," said Tzachi Levy, GM of the company's Aseptic Plant. "Our advanced aseptic manufacturing capabilities and commitment to excellence ensure that the necessary components for this cutting-edge therapy will be produced to the highest standards. Our expertise supports the process whether a small start-up, a CRO provider, or a well-established pharma company."

About LIVEKIDNEY.BIO
LIVEKIDNEY.BIO is a clinical-stage biotech company focused on developing innovative therapeutic solutions for kidney diseases, particularly lupus nephritis. Through advanced research and cutting-edge technology, the company is committed to improving the lives of patients by providing more effective and safer treatment options than those currently available.

About Isotopia
Isotopia is a global leader in radiopharmaceutical solutions, specializing in high-quality aseptic and lyophilized drug products for clinical trials and commercial use. With our state-of-the-art aseptic plant and strict adherence to GMP and FDA standards, we deliver tailored solutions that guarantee safety, precision, and innovation in every product.

Contact:

[email protected] 

Logo - https://mma.prnewswire.com/media/2337282/4537248/Isotopia_Logo.jpg

SOURCE Isotopia

Modal title

Also from this source

ASP Isotopes and Isotopia Announce Supply Agreement for Gadolinium-160 to Accelerate Terbium-161 Production for Advanced Cancer Therapies

ASP Isotopes and Isotopia Announce Supply Agreement for Gadolinium-160 to Accelerate Terbium-161 Production for Advanced Cancer Therapies

ASP Isotopes Inc. (NASDAQ: ASPI) and Isotopia Molecular Imaging Ltd. have entered into a strategic agreement to secure the supply of Gadolinium-160...

ASP Isotopes and Isotopia Announce Supply Agreement for Gadolinium-160 to Accelerate Terbium-161 Production for Advanced Cancer Therapies

ASP Isotopes and Isotopia Announce Supply Agreement for Gadolinium-160 to Accelerate Terbium-161 Production for Advanced Cancer Therapies

ASP Isotopes Inc. (NASDAQ: ASPI) and Isotopia Molecular Imaging Ltd. have entered into a strategic agreement to secure the supply of Gadolinium-160...

More Releases From This Source

Explore

Health Care & Hospitals

Health Care & Hospitals

Biotechnology

Biotechnology

Medical Pharmaceuticals

Medical Pharmaceuticals

Pharmaceuticals

Pharmaceuticals

News Releases in Similar Topics

Contact PR Newswire

  • +972-77-2005042
    from 8 AM - 11 PM IL

Global Sites

  • APAC
  • APAC - Traditional Chinese
  • Asia
  • Brazil
  • Canada
  • Czech
  • Denmark
  • Finland
  • France
  • Germany

 

  • India
  • Indonesia
  • Israel
  • Italy
  • Mexico
  • Middle East
  • Middle East - Arabic
  • Netherlands
  • Norway
  • Poland

 

  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United Kingdom
  • United States

Do not sell or share my personal information:

  • Submit via [email protected] 
  • Call Privacy toll-free: 877-297-8921
Global Sites
  • Asia
  • Brazil
  • Canada
  • Csezh
  • Denmark
  • Finland
  • France
  • Germany
  • India
  • Israel
  • Italie
  • Mexico
  • Middle East
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United Kingdom
  • United States
+972-77-2005042
from 8 AM - 11 PM IL
  • Terms of Use
  • Privacy Policy
  • Information Security Policy
  • Site Map
  • Cookie Settings
Copyright © 2026 Cision US Inc.